MEA Interstitial Cystitis Market - Industry Trends and Forecast to 2029

Description

List of Tables

The Middle East and Africa interstitial cystitis market are projected to register a substantial CAGR of 5.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

By Severity (Mild to Moderate and Moderate to Severe), Treatment Type (Medications, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation, and Surgery), Route of Administration (Oral, Parenteral, Intravesical, Topical, and Others), Mode of Purchase (Over The Counter and Prescription), Patient Type (Pediatric and Adults), End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of the Middle East and Africa), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Middle East and Africa interstitial cystitis market are:

Increasing prevalence of interstitial cystitis
Rise in healthcare expenditure

Market Players:

Some of the major players operating in the Middle East and Africa interstitial cystitis market are:

Hikma Pharmaceuticals
Sandoz AG
Sun Pharmaceutical Industries Ltd.
Accord-UK Ltd
Pfizer, Inc.
Strides Pharma Science Limited
Apotex Inc.
Aurobindo Pharma USA
Dr. Reddy's Laboratories, Inc.
Bayer AG
Reckitt Benckiser Group PLC

1 INTRODUCTION 57

1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET 57
1.4 LIMITATIONS 58
1.5 MARKETS COVERED 59

2 MARKET SEGMENTATION 61

2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 CURRENCY AND PRICING 63
2.5 DBMR TRIPOD DATA VALIDATION MODEL 64
2.6 MULTIVARIATE MODELLING 67
2.7 TYPE LIFELINE CURVE 67
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.9 DBMR MARKET POSITION GRID 69
2.10 MARKET APPLICATION COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72

3 EXECUTIVE SUMMARY 73

4 PREMIUM INSIGHTS 75

4.1 PESTEL ANALYSIS 76
4.2 PORTER'S FIVE FORCES 77
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET 78
4.4 EPIDEMIOLOGY 79

5 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: REGULATIONS 80

5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES 80
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES 81
5.3 JAPAN REGULATORY GUIDANCE 82

6 MARKET OVERVIEW 83

6.1 DRIVERS 85
- 6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC) 85
- 6.1.2 RISE IN HEALTHCARE EXPENDITURE 85
- 6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS 86
- 6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY 86
- 6.1.5 RISING DISEASE MANAGEMENT PROGRAMS 86
6.2 RESTRAINTS 87
- 6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS 87
- 6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS 87
- 6.2.3 DEARTH OF SKILLED PROFESSIONALS 88
6.3 OPPORTUNITIES 88
- 6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 88
- 6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES 89
- 6.3.3 IMPROVING HEALTHCARE SYSTEM 89
- 6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES 89
6.4 CHALLENGES 90
- 6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 90
- 6.4.2 PATENT EXPIRY OF DRUGS 91

7 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY 92

7.1 OVERVIEW 93
7.2 MILD TO MODERATE 96
7.3 MODERATE TO SEVERE 96

8 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE 97

8.1 OVERVIEW 98
8.2 MEDICATIONS 101
- 8.2.1 ANALGESICS 101
  - 8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 102
    - 8.2.1.1.1 IBUPROFEN 102
    - 8.2.1.1.2 NAPROXEN 102
    - 8.2.1.1.3 OTHERS 102
  - 8.2.1.2 ACETAMINOPHEN 102
  - 8.2.1.3 NON-NARCOTIC PAIN MEDICATION 102
    - 8.2.1.3.1 METHENAMINE 103
    - 8.2.1.3.2 PHENAZOPYRIDINE 103
    - 8.2.1.3.3 OTHERS 103
  - 8.2.1.4 NARCOTIC PAIN MEDICATION 103
    - 8.2.1.4.1 CODEINE 104
    - 8.2.1.4.2 HYDROCODONE 104
    - 8.2.1.4.3 OXYCODONE 104
    - 8.2.1.4.4 OXYMORPHONE 104
    - 8.2.1.4.5 MORPHINE 104
    - 8.2.1.4.6 HYDROMORPHONE 104
    - 8.2.1.4.7 METHADONE 105
    - 8.2.1.4.8 OTHERS 105
- 8.2.2 ANTIHISTAMINES 105
  - 8.2.2.1 LORATADINE 105
  - 8.2.2.2 HYDROXYZINE 105
  - 8.2.2.3 OTHERS 105
- 8.2.3 TRICYCLIC ANTIDEPRESSANTS 105
  - 8.2.3.1 AMITRIPTYLINE 106
  - 8.2.3.2 IMIPRAMINE 106
  - 8.2.3.3 OTHERS 106
- 8.2.4 IMMUNOSUPPRESSANTS 106
  - 8.2.4.1 CYCLOSPORINE 106
  - 8.2.4.2 MYCOPHENOLATE 106
  - 8.2.4.3 OTHERS 107
- 8.2.5 PENTOSAN POLYSULFATE SODIUM 107
- 8.2.6 OTHERS 107
  - 8.2.6.1 ALPHA BLOCKERS 107
    - 8.2.6.1.1 DOXAZOSIN 108
    - 8.2.6.1.2 TERAZOSIN 108
    - 8.2.6.1.3 TAMSULOSIN 108
    - 8.2.6.1.4 OTHERS 108
  - 8.2.6.2 AMPHETAMINES 108
  - 8.2.6.3 LEUKOTRIENE INHIBITORS 108
    - 8.2.6.3.1 MONTELUKAST 109
    - 8.2.6.3.2 ZAFIRLUKAST 109
    - 8.2.6.3.3 OTHERS 109
  - 8.2.6.4 OTHERS 109
8.3 BLADDER INSTILLATIONS 109
- 8.3.1 DIMETHYL SULFOXIDE 110
- 8.3.2 HEPARIN 110
- 8.3.3 OTHERS 110
8.4 BOTULINUM TOXIN A 110
8.5 SURGERY 111
- 8.5.1 FULGURATION 111
- 8.5.2 RESECTION 111
- 8.5.3 BLADDER AUGMENTATION 111
8.6 NERVE STIMULATIONS 111

9 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION 113

9.1 OVERVIEW 114
9.2 ORAL 117
- 9.2.1 TABLETS 117
  - 9.2.1.1 EXTENDED RELEASE 118
  - 9.2.1.2 IMMEDIATE RELEASE 118
- 9.2.2 CAPSULES 118
- 9.2.3 OTHERS 118
9.3 PARENTERAL 118
9.4 INTRAVESICAL 119
9.5 TOPICAL 119
9.6 OTHERS 120

10 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE 121

10.1 OVERVIEW 122
10.2 OVER THE COUNTER 125
10.3 PRESCRIPTION 125

11 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE 126

11.1 OVERVIEW 127
11.2 ADULTS 130
11.3 PEDIATRIC 130

12 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY END USER 131

12.1 OVERVIEW 132
12.2 HOSPITALS 135
12.3 CLINICS 135
12.4 HOME HEALTHCARE 136
12.5 OTHERS 136

13 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL 137

13.1 OVERVIEW 138
13.2 DIRECT TENDER 141
13.3 RETAIL SALES 141
- 13.3.1 PHARMACY STORES 142
- 13.3.2 ONLINE RETAIL CHANNEL 142
- 13.3.3 OTHERS 142
13.4 OTHERS 142

14 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY 143

14.1 MIDDLE EAST AND AFRICA 144
- 14.1.1 SAUDI ARABIA 155
- 14.1.2 SOUTH AFRICA 161
- 14.1.3 UAE 167
- 14.1.4 EGYPT 173
- 14.1.5 ISRAEL 179
- 14.1.6 REST OF MIDDLE EAST AND AFRICA 185

15 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE 186

15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 186

16 SWOT ANALYSIS 187

17 COMPANY PROFILE 188

17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD. 188
- 17.1.1 COMPANY SNAPSHOT 188
- 17.1.2 REVENUE ANALYSIS 188
- 17.1.3 PRODUCT PORTFOLIO 189
- 17.1.4 RECENT DEVELOPMENTS 189
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG) 190
- 17.2.1 COMPANY SNAPSHOT 190
- 17.2.2 REVENUE ANALYSIS 190
- 17.2.3 COMPANY SHARE ANALYSIS 191
- 17.2.4 PRODUCT PORTFOLIO 191
- 17.2.5 RECENT DEVELOPMENT 191
17.3 HIKMA PHARMACEUTICALS PLC 192
- 17.3.1 COMPANY SNAPSHOT 192
- 17.3.2 REVENUE ANALYSIS 192
- 17.3.3 COMPANY SHARE ANALYSIS 193
- 17.3.4 PRODUCT PORTFOLIO 193
- 17.3.5 RECENT DEVELOPMENTS 193
17.4 DR. REDDY'S LABORATORIES LTD 194
- 17.4.1 COMPANY SNAPSHOT 194
- 17.4.2 REVENUE ANALYSIS 194
- 17.4.3 COMPANY SHARE ANALYSIS 195
- 17.4.4 PRODUCT PORTFOLIO 195
- 17.4.5 RECENT DEVELOPMENT 196
17.5 BAYER AG 197
- 17.5.1 COMPANY SNAPSHOT 197
- 17.5.2 REVENUE ANALYSIS 197
- 17.5.3 COMPANY SHARE ANALYSIS 198
- 17.5.4 PRODUCT PORTFOLIO 198
- 17.5.5 RECENT DEVELOPMENT 198
17.6 AMNEAL PHARMACEUTICAL LLC. 199
- 17.6.1 COMPANY SNAPSHOT 199
- 17.6.2 REVENUE ANALYSIS 199
- 17.6.3 PRODUCT PORTFOLIO 200
- 17.6.4 RECENT DEVELOPMENTS 200
17.7 APOTEX 201
- 17.7.1 COMPANY SNAPSHOT 201
- 17.7.2 PRODUCT PORTFOLIO 201
- 17.7.3 RECENT DEVELOPMENT 201
17.8 AUROBINDO PHARMA USA 202
- 17.8.1 COMPANY SNAPSHOT 202
- 17.8.2 REVENUE ANALYSIS 202
- 17.8.3 PRODUCT PORTFOLIO 203
- 17.8.4 RECENT DEVELOPMENT 203
17.9 AVET PHARMACEUTICALS INC. 204
- 17.9.1 COMPANY SNAPSHOT 204
- 17.9.2 PRODUCT PORTFOLIO 204
- 17.9.3 RECENT DEVELOPMENT 204
17.10 ALVOGEN 205
- 17.10.1 COMPANY SNAPSHOT 205
- 17.10.2 PRODUCT PORTFOLIO 205
- 17.10.3 10.3RECENT DEVELOPMENT 205
17.11 ACCORD-UK LTD 206
- 17.11.1 COMPANY SNAPSHOT 206
- 17.11.2 PRODUCT PORTFOLIO 206
- 17.11.3 11.3RECENT DEVELOPMENT 206
17.12 GLAXOSMITHKLINE PLC 207
- 17.12.1 COMPANY SNAPSHOT 207
- 17.12.2 12.2REVENUE ANALYSIS 207
- 17.12.3 PRODUCT PORTFOLIO 208
- 17.12.4 RECENT DEVELOPMENT 208
17.13 JOHNSON & JOHNSON SERVICES, INC. 209
- 17.13.1 COMPANY SNAPSHOT 209
- 17.13.2 REVENUE ANALYSIS 209
- 17.13.3 PRODUCT PORTFOLIO 210
- 17.13.4 RECENT DEVELOPMENT 210
17.14 LANNETT 211
- 17.14.1 COMPANY SNAPSHOT 211
- 17.14.2 REVENUE ANALYSIS 211
- 17.14.3 PRODUCT PORTFOLIO 212
- 17.14.4 RECENT DEVELOPMENT 212
17.15 PRESTIGE CONSUMER HEALTHCARE 213
- 17.15.1 COMPANY SNAPSHOT 213
- 17.15.2 REVENUE ANALYSIS 213
- 17.15.3 PRODUCT PORTFOLIO 214
- 17.15.4 RECENT DEVELOPMENTS 214
17.16 PFIZER INC. 215
- 17.16.1 COMPANY SNAPSHOT 215
- 17.16.2 REVENUE ANALYSIS 215
- 17.16.3 PRODUCT PORTFOLIO 216
- 17.16.4 RECENT DEVELOPMENT 216
17.17 RECKITT BENCKISER GROUP PLC. 217
- 17.17.1 COMPANY SNAPSHOT 217
- 17.17.2 REVENUE ANALYSIS 217
- 17.17.3 PRODUCT PORTFOLIO 217
- 17.17.4 RECENT DEVELOPMENT 218
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD. 219
- 17.18.1 COMPANY SNAPSHOT 219
- 17.18.2 REVENUE ANALYSIS 219
- 17.18.3 PRODUCT PORTFOLIO 220
- 17.18.4 RECENT DEVELOPMENT 220
17.19 STRIDES PHARMA SCIENCE LIMITED. 221
- 17.19.1 COMPANY SNAPSHOT 221
- 17.19.2 REVENUE ANALYSIS 221
- 17.19.3 PRODUCT PORTFOLIO 222
- 17.19.4 RECENT DEVELOPMENT 222
17.20 VIATRIS INC. 223
- 17.20.1 COMPANY SNAPSHOT 223
- 17.20.2 REVENUE ANALYSIS 223
- 17.20.3 PRODUCT PORTFOLIO 224
- 17.20.4 RECENT DEVELOPMENT 224
17.21 VISTA PHARM INC. 225
- 17.21.1 COMPANY SNAPSHOT 225
- 17.21.2 PRODUCT PORTFOLIO 225
- 17.21.3 RECENT DEVELOPMENTS 225
17.22 ZYDUS PHARMACEUTICALS INC., 226
- 17.22.1 COMPANY SNAPSHOT 226
- 17.22.2 REVENUE ANALYSIS 226
- 17.22.3 PRODUCT PORTFOLIO 227
- 17.22.4 RECENT DEVELOPMENTS 227

18 QUESTIONNAIRE 228

19 RELATED REPORTS 231

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 26
FIGURE 2 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION 29
FIGURE 3 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DROC ANALYSIS 30
FIGURE 4 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 31
FIGURE 5 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS 31
FIGURE 6 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS 33
FIGURE 7 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID 34
FIGURE 8 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID 35
FIGURE 9 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 39
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 40
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029 40
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET 49
FIGURE 14 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021 58
FIGURE 15 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION) 59
FIGURE 16 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029) 59
FIGURE 17 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE 60
FIGURE 18 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021 63
FIGURE 19 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION) 64
FIGURE 20 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029) 64
FIGURE 21 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 65
FIGURE 22 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 79
FIGURE 23 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 80
FIGURE 24 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 80
FIGURE 25 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 81
FIGURE 26 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021 87
FIGURE 27 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 88
FIGURE 28 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029) 88
FIGURE 29 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 89
FIGURE 30 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021 92
FIGURE 31 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 93
FIGURE 32 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029) 93
FIGURE 33 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE 94
FIGURE 34 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021 97
FIGURE 35 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION) 98
FIGURE 36 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029) 98
FIGURE 37 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE 99
FIGURE 38 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021 103
FIGURE 39 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 104
FIGURE 40 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 104
FIGURE 41 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 105
FIGURE 42 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 110
FIGURE 43 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 112
FIGURE 44 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 112
FIGURE 45 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 113
FIGURE 46 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 113
FIGURE 47 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 151